See results from clinical trials with Trulicity when assessed for A1C reduction, weight change and CV risk reduction.

Nutrients, Free Full-Text

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice

Frontiers Changes in body weight and cardiovascular risk factors in a Chinese population with type 2 diabetes mellitus: a longitudinal study

Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP

Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP

Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Diabetes Canada Clinical Practice Guidelines

The Official Journal of ATTD Advanced Technologies & Treatments for Diabetes Conference Madrid, Spain—February 19–22, 2020

ABSTRACTS ADDRM 2022 Nederlands Tijdschrift voor Diabetologie

Heart Failure, FARXIGA® (dapagliflozin) 5 mg & 10 mg tablets

Clinical Trials: Lowereing A1C, Weight Change & CV Data, HCP